PMID- 23782659
OWN - NLM
STAT- MEDLINE
DCOM- 20131105
LR  - 20151119
IS  - 1526-9248 (Print)
IS  - 1526-9248 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Jun
TI  - Heart transplant with donor-specific antibody after immunoadsorption plus 
      rituximab: a case report.
PG  - 128-31
LID - 10.7182/pit2013454 [doi]
AB  - Different desensitization strategies are available for treating patients with 
      preformed human leukocyte antigen (HLA) antibodies. A highly presensitized heart 
      recipient received immunoadsorption and rituximab therapy. The patient, with 
      end-stage heart failure, was positive only for antibodies of HLA class I 
      (anti-A2, A10, B17), and Luminex platform (One Lambda kit) showed a 
      panel-reactive antibody score of 64%. The patient's serum was tested repeatedly 
      in both complement-dependent cytotoxicity and flow-cytometry crossmatches against 
      cells from different potential organ donors. The results of these crossmatches 
      were positive on flow cytometry when tested with HLA-A2, A10, and B17 but were 
      still negative on cytotoxicity. The patient was treated with a desensitization 
      regimen; this treatment immediately decreased antibody levels of 70% and the 
      patient subsequently received a transplant with donor-specific HLA antibody 
      (HLA-A2). After more than 2 years, graft function remains normal and the clinical 
      status of the patient is stable.
FAU - Resse, Marianna
AU  - Resse M
AD  - Second University of Naples, Italy. marianna.resse@unina2.it
FAU - Maiello, Ciro
AU  - Maiello C
FAU - Cacciatore, Francesco
AU  - Cacciatore F
FAU - Romano, Gianpaolo
AU  - Romano G
FAU - Sabia, Chiara
AU  - Sabia C
FAU - Picascia, Antonietta
AU  - Picascia A
FAU - Ursomando, Fabio
AU  - Ursomando F
FAU - Napoli, Claudio
AU  - Napoli C
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Prog Transplant
JT  - Progress in transplantation (Aliso Viejo, Calif.)
JID - 100909380
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (HLA-A Antigens)
RN  - 0 (Immunoglobulins)
RN  - 0 (Immunologic Factors)
RN  - 0 (Immunosorbents)
RN  - 0 (Isoantibodies)
RN  - 4F4X42SYQ6 (Rituximab)
MH  - Adult
MH  - Antibodies, Monoclonal, Murine-Derived/administration & dosage/*immunology
MH  - Desensitization, Immunologic/methods
MH  - Flow Cytometry
MH  - Graft Survival
MH  - HLA-A Antigens/immunology
MH  - Heart Transplantation/*immunology
MH  - Histocompatibility Testing/methods
MH  - Humans
MH  - Immunoglobulins/*administration & dosage
MH  - Immunologic Factors/*administration & dosage
MH  - Immunosorbents/*therapeutic use
MH  - Isoantibodies/*immunology
MH  - Male
MH  - Rituximab
EDAT- 2013/06/21 06:00
MHDA- 2013/11/06 06:00
CRDT- 2013/06/21 06:00
PHST- 2013/06/21 06:00 [entrez]
PHST- 2013/06/21 06:00 [pubmed]
PHST- 2013/11/06 06:00 [medline]
AID - B653332159W85V64 [pii]
AID - 10.7182/pit2013454 [doi]
PST - ppublish
SO  - Prog Transplant. 2013 Jun;23(2):128-31. doi: 10.7182/pit2013454.